Directors' Dealings
July 23 2009 - 11:17AM
UK Regulatory
TIDMIMM
RNS Number : 2020W
Immupharma PLC
23 July 2009
+----------------------------------------+--------------------------------------------+
| For Immediate Release | 23 July 2009 |
+----------------------------------------+--------------------------------------------+
ImmuPharma PLC
Directors' Dealings
Institutions increase stake
ImmuPharma PLC ('ImmuPharma' or the 'Company') (LSE:IMM) announces that a number
of existing and new blue-chip institutional investors have purchased shares
from Richard Warr and the Trusts of Richard Warr and Dimitri Dimitriou, who are
two of ImmuPharma's founders and Directors. A total of 12.5 million ordinary
shares (16.1% of the issued share capital) of 10 pence each in the Company, were
placed by Noble & Company Limited at a price of 86 pence per share to
institutional investors on 23 July 2009. Panmure Gordon is the NOMAD and
Corporate Broker to the Company.
Following the disposal, the current holdings directly or through Trust are:
+-------------------+-----------+--------------+-------------+
| | Ordinary | Ordinary | Percentage |
| | Shares | Shares | of shares |
| | Sold | Retained | in issue |
+-------------------+-----------+--------------+-------------+
| Richard Warr (1) | 6,250,000 | 3,528,968 | 4.6% |
+-------------------+-----------+--------------+-------------+
| Dimitri Dimitriou | 6,250,000 | 3,528,969 | 4.6% |
| (2) | | | |
+-------------------+-----------+--------------+-------------+
| Dr Zimmer & | 0 | 23,056,602 | 29.8% |
| Family | | | |
+-------------------+-----------+--------------+-------------+
(1) Ordinary shares of GBP0.10 held by Louvre Trustees Limited where the Warr
family has a beneficial interest and shares held directly by Richard Warr.
(2) Ordinary shares of GBP0.10 held by Louvre Trustees Limited where the
Dimitriou family has a beneficial interest.
Richard Warr, ImmuPharma's Chairman said: "We are delighted with the support
received from our existing investors and the demand from new investors including
M&G Investments. The allocation of these shares further increases ImmuPharma's
free float with the aim of improving overall liquidity."
For further information please contact:
+--------------------------------------+-----------------------------------+
| ImmuPharma PLC | +44 20 7152 4080 |
+--------------------------------------+-----------------------------------+
| Dimitri Dimitriou, Chief Executive | |
| Officer | |
+--------------------------------------+-----------------------------------+
| Richard Warr, Chairman | |
+--------------------------------------+-----------------------------------+
| | |
+--------------------------------------+-----------------------------------+
| Panmure Gordon | +44 151 243 0963 |
+--------------------------------------+-----------------------------------+
| Andrew Burnett/ Rakesh Sharma | |
+--------------------------------------+-----------------------------------+
| | |
+--------------------------------------+-----------------------------------+
| Noble & Company Limited | +44 20 7763 2335 |
+--------------------------------------+-----------------------------------+
| John Millar | |
+--------------------------------------+-----------------------------------+
| | |
+--------------------------------------+-----------------------------------+
| Buchanan Communications | +44 20 7466 5000 |
+--------------------------------------+-----------------------------------+
| Lisa Baderoon | |
+--------------------------------------+-----------------------------------+
| Rebecca Skye Dietrich | |
+--------------------------------------+-----------------------------------+
More information on the Company can be found at www.immupharma.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSSELFIDSUSEFW
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024
